Core Viewpoint - The conference on high-quality development of traditional Chinese medicine (TCM) highlighted the strategic layout of Guoshengtang in promoting the internationalization of TCM through "management empowerment + AI technology + products" to establish itself as the leading TCM health brand for the global Chinese community [1] Group 1: Management Strategy - Guoshengtang has initiated its internationalization journey by acquiring Singapore's Baozhongtang, achieving a revenue increase of 119% year-on-year by July 2025 [1] - The company plans to expand to 30 clinics in Singapore by the end of 2026, leveraging its successful operational model from China [1] - The company employs a multi-faceted strategy for overseas expansion, including self-built flagship stores, strategic partnerships, and acquisitions of local medical institutions [2] Group 2: AI Technology - Guoshengtang launched 10 AI avatars of renowned TCM doctors to address the shortage of quality TCM talent overseas, enhancing the internationalization of TCM [2][3] - The AI avatars have achieved over 86% consistency with expert simulations, improving diagnostic accuracy and medication rationality [4] - The AI technology aids in alleviating the scarcity of quality TCM resources and enhances the efficiency of top experts, while also supporting the training of younger doctors [4] Group 3: Product Development - Guoshengtang has made significant advancements in the development of traditional Chinese medicine (TCM) products, with its first proprietary TCM product receiving certification in Singapore [5][6] - The company has initiated a project to create an integrated platform for clinical evaluation of TCM, leveraging AI and big data to enhance clinical research and innovation [6] - Guoshengtang aims to strengthen its product development efforts, focusing on innovative TCM formulations and ensuring the legacy of renowned TCM practitioners through its products [7]
固生堂(02273)：“三驾马车”加速出海 打造全球中医第一品牌